Vor Biopharma

Robert Ang, President and CEO

April 12 | 11:30am | BioCentriq Ballroom 

Cambridge, MA

(NASDAQ: VOR)

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.

www.vorbio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions